Patients With Homozygous and Heterozygous Familial Hypercholesterolemia research hub

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-OLE)

This study looks at a new drug, Lerodalcibep (LIB003), for people with very high cholesterol that's hard to control. It's an extension of previous studies, checking if the drug keeps working and remains safe over a longer time to help reduce 'bad' cholesterol.